These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32685589)

  • 1. High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study.
    Kanter J; Bhor M; Li X; Li FY; Paulose J
    J Health Econ Outcomes Res; 2019; 6(3):174-184. PubMed ID: 32685589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
    Udeze C; Evans KA; Yang Y; Lillehaugen T; Manjelievskaia J; Mujumdar U; Li N; Andemariam B
    Adv Ther; 2023 Aug; 40(8):3543-3558. PubMed ID: 37332020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study.
    Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
    J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 32685602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study.
    Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
    J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 36873574
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
    Marfo K; Dei-Adomakoh Y; Segbefia C; Dwomoh D; Edgal A; Ampah N; Ramachandrachar BC; Subramanyam K; Natarajan A; Egbujo O; Ataga KI
    BMC Health Serv Res; 2023 Sep; 23(1):1018. PubMed ID: 37735428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sickle cell disease complications: Prevalence and resource utilization.
    Shah N; Bhor M; Xie L; Paulose J; Yuce H
    PLoS One; 2019; 14(7):e0214355. PubMed ID: 31276525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study.
    Shah N; Bhor M; Xie L; Paulose J; Yuce H
    J Health Econ Outcomes Res; 2020; 7(1):52-60. PubMed ID: 32685598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.
    Shah NR; Bhor M; Latremouille-Viau D; Kumar Sharma V; Puckrein GA; Gagnon-Sanschagrin P; Khare A; Kumar Singh M; Serra E; Davidson M; Xu L; Guerin A
    J Med Econ; 2020 Nov; 23(11):1345-1355. PubMed ID: 32815766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Vaso-occlusive Crises in United States Sickle Cell Disease Patients: A Retrospective Claims-based Study.
    Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
    J Health Econ Outcomes Res; 2019; 6(3):106-117. PubMed ID: 32685584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Hydroxyurea Therapy in Reducing Pain Crises, Hospital Admissions, and Length of Stay Among Sickle Cell Patients in the Eastern Region of Saudi Arabia.
    Albohassan H; Ammen M; Alomran AA; Bu Shehab H; Al Sakkak H; Al Bohassan A
    Cureus; 2022 Nov; 14(11):e31527. PubMed ID: 36540486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries.
    Desai RJ; Mahesri M; Globe D; Mutebi A; Bohn R; Achebe M; Levin R; Schneeweiss S
    Ann Hematol; 2020 Nov; 99(11):2497-2505. PubMed ID: 32869184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis.
    Gallagher ME; Chawla A; Brady BL; Badawy SM
    J Med Econ; 2022; 25(1):1140-1148. PubMed ID: 36222016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis.
    Olson AL; Hartmann N; Patnaik P; Garry EM; Bohn RL; Singer D; Baldwin M; Wallace L
    Adv Ther; 2022 Apr; 39(4):1794-1809. PubMed ID: 35199282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare resource utilization and costs 2 years pre- and post-lumbar spine surgery for stenosis: a national claims cohort study of 22,182 cases.
    Koltsov JCB; Sambare TD; Alamin TF; Wood KB; Cheng I; Hu SS
    Spine J; 2022 Jun; 22(6):965-974. PubMed ID: 35123048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transition to adult care in sickle cell disease: A longitudinal study of clinical characteristics and disease severity.
    Kayle M; Docherty SL; Sloane R; Tanabe P; Maslow G; Pan W; Shah N
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27463. PubMed ID: 30251318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
    Blinder MA; Vekeman F; Sasane M; Trahey A; Paley C; Duh MS
    Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare costs and resource utilization in patients with severe aplastic anemia in the US.
    Cai B; Said Q; Li X; Li FY; Arcona S
    J Med Econ; 2019 Oct; 22(10):1055-1062. PubMed ID: 31296074
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
    Kang HA; Barner JC; Lawson KA; Rascati K; Mignacca RC
    Am J Hematol; 2023 Jan; 98(1):90-101. PubMed ID: 36251408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
    Vekeman F; Sasane M; Cheng WY; Ramanakumar AV; Fortier J; Qiu Y; Duh MS; Paley C; Adams-Graves P
    J Med Econ; 2016; 19(3):292-303. PubMed ID: 26618853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of healthcare utilization among patients with sickle cell disease hospitalized with pain crises.
    Rodday AM; Esham KS; Savidge N; Parsons SK
    EJHaem; 2020 Nov; 1(2):438-447. PubMed ID: 34350423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.